The standard biomarkers that significantly predict the recurrence and progression of prostate cancer and choice of therapy are based on the validation of prostate-specific antigen (PSA) and pathological grade using Gleason score (GS) [3,4,5]. Here, KLK3 is linked to Familial prostate cancer.